Our results implied an interaction between ERK1/2 and JNK MAPK, as co-treatment with alpinumisoflavone and the JNK MAPK inhibitor SP600125 suppressed the viability of HCC cells more than treatment with alpinumisoflavone alone. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.